$HALO SEC Filings

Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.19M) · Received 20,000 shares by exercise or conversion ($368K) · 3 more

Received 3,796 shares as a grant or award

Received 1,169 shares as a grant or award · Granted 1,775 Option to Purchase Common Stock

No securities owned

Sold 5,230 shares ($568K)

(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders ...

INDENTURE, dated as of September 22, 2026, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee,...

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Sold 18,996 shares ($2.05M)

SAN DIEGO, CA, September 16, 2026 — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amo...

Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.15M) · Received 20,000 shares by exercise or conversion ($368K) · 3 more

Received 1,161 shares as a grant or award · Granted 1,778 Option to Purchase Common Stock

No securities owned

Received 20,000 shares by exercise or conversion ($368K) · Sold 20,000 shares ($2.05M) · Received 20,000 shares by exercise or conversion ($368K) · 3 more

Sold 1,626 shares ($167K)